Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction
NCT ID: NCT07325955
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
194 participants
OBSERVATIONAL
2020-10-01
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)
NCT03504202
Effect of Trimetazidine During the Primary PCI on Cardiac Function in Patients With ST-elevation Myocardial Infarction
NCT02826616
Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction
NCT02798874
Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.
NCT03797729
The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease
NCT02107144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trimetazidine treatment group
Patients with trimetazidine treatment
No interventions assigned to this group
Control group
Patients without Trimetazidine treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qian geng
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese PLA general hospital
Beijing, Haidian, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Singh D, Oladimeji-Salami J, Akindele AJ. New insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review. Eur J Pharmacol. 2024 Dec 15;985:177062. doi: 10.1016/j.ejphar.2024.177062. Epub 2024 Oct 19.
Demirelli S, Karakelleoglu S, Gundogdu F, Tas MH, Kaya A, Duman H, Degirmenci H, Hamur H, Simsek Z. The Impact of Trimetazidine Treatment on Left Ventricular Functions and Plasma Brain Natriuretic Peptide Levels in Patients with Non-ST Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Korean Circ J. 2013 Jul;43(7):462-7. doi: 10.4070/kcj.2013.43.7.462. Epub 2013 Jul 31.
Shehata M. Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis. Cardiol Res. 2014 Apr;5(2):58-67. doi: 10.14740/cr330w. Epub 2014 May 15.
Li R, Tang X, Jing Q, Wang Q, Yang M, Han X, Zhao J, Yu X. The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI. Am J Emerg Med. 2017 Nov;35(11):1657-1661. doi: 10.1016/j.ajem.2017.05.024. Epub 2017 May 23.
Li Y, Wang D, Hu C, Zhang P, Zhang D, Qin S. Efficacy and Safety of Adjunctive Trimetazidine Therapy for Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. Cardiology. 2016;135(3):188-195. doi: 10.1159/000446640. Epub 2016 Jul 15.
Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol. 2008 Oct;6(4):282-91. doi: 10.2174/157016108785909788.
El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5(4):271-8. doi: 10.2165/00129784-200505040-00006.
Kim JS, Kim CH, Chun KJ, Kim JH, Park YH, Kim J, Choi JH, Lee SH, Kim EJ, Yu DG, Ahn EY, Jeong MH. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry. Clin Res Cardiol. 2013 Dec;102(12):915-22. doi: 10.1007/s00392-013-0611-0. Epub 2013 Aug 28.
Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, Paganelli F. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart. 2007 Jun;93(6):703-7. doi: 10.1136/hrt.2006.107524. Epub 2007 May 8.
Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006 Sep 5;48(5):992-8. doi: 10.1016/j.jacc.2006.03.060. Epub 2006 Aug 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SF2020-2-5012
Identifier Type: OTHER
Identifier Source: secondary_id
TMZAMI002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.